Major US insurer to cover use of HIFU for treatment of radiorecurrent prostate cancer
According to a media release issued on March 18 by EDAP TMS, the US healthcare insurance firm CIGNA has agreed to cover the use of high-intensity focal ultrasound (HIFU) as a second-line, salvage therapy for men with radiorecurrent prostate cancer.
Specifically, to quote the media release from EDAP TMS: